NYSE:CANF Can-Fite BioPharma (CANF) Stock Price, News & Analysis $2.24 0.00 (0.00%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$2.24 +0.00 (+0.04%) As of 09/18/2026 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsNews and TrendsOwnershipSEC Filings About Can-Fite BioPharma Stock (NYSE:CANF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Can-Fite BioPharma alerts:Sign Up Key Stats Today's Range$2.23▼$2.2750-Day Range$2.16▼$3.5852-Week Range$2.16▼$13.20Volume43,616 shsAverage Volume1.03 million shsMarket Capitalization$1.47 millionP/E RatioN/ADividend YieldN/APrice Target$44.00Consensus RatingModerate Buy Company Overview Can-Fite BioPharma Ltd. is an Israeli clinical-stage biopharmaceutical company developing orally administered small-molecule drugs for inflammatory, metabolic, liver and cancer-related diseases. The company’s research is based primarily on compounds that target the A3 adenosine receptor, a receptor believed to play a role in regulating immune and inflammatory responses. Can-Fite’s lead candidates include piclidenoson, also known as CF101, which has been studied for conditions such as rheumatoid arthritis and psoriasis, and namodenoson, also known as CF102, which is being developed for liver-related diseases including metabolic dysfunction-associated steatohepatitis and hepatocellular carcinoma. The company has also investigated additional applications for its A3 adenosine receptor platform, including potential treatments for other inflammatory, oncological and metabolic disorders. Founded in 1994, Can-Fite conducts research and clinical development activities in Israel and internationally, including through studies involving patients and regulatory interactions in the United States and other markets. The company was founded by Dr. Pnina Fishman, who has served as its chief executive officer and has been associated with the development of its A3 adenosine receptor-based platform. Can-Fite’s products remain in clinical development and are not broadly marketed as approved commercial therapies.AI Generated. May Contain Errors. Read More Can-Fite BioPharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks34th Percentile Overall ScoreCANF MarketRank™: Can-Fite BioPharma scored higher than 34% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingCan-Fite BioPharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and no sell ratings.Upside PotentialCan-Fite BioPharma has a consensus price target of $44.00, representing about 1,864.3% upside from its current price of $2.24.Amount of Analyst CoverageCan-Fite BioPharma has only been the subject of 1 research reports in the past 90 days.Read more about Can-Fite BioPharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Can-Fite BioPharma are expected to grow in the coming year, from ($1.25) to ($0.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Can-Fite BioPharma is -1.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Can-Fite BioPharma is -1.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCan-Fite BioPharma has a P/B Ratio of 1.27. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for CANF. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCan-Fite BioPharma does not currently pay a dividend.Dividend GrowthCan-Fite BioPharma does not have a long track record of dividend growth. News and Social Media1.3 / 5News SentimentN/A Search Interest5 people have searched for CANF on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Can-Fite BioPharma to their MarketBeat watchlist in the last 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Can-Fite BioPharma insiders have not sold or bought any company stock.Percentage Held by Insiders0.80% of the stock of Can-Fite BioPharma is held by insiders.Percentage Held by Institutions21.00% of the stock of Can-Fite BioPharma is held by institutions.Read more about Can-Fite BioPharma's insider trading history. Receive CANF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Can-Fite BioPharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CANF Stock News HeadlinesAnalyzing Veru (NASDAQ:VERU) and Can-Fite BioPharma (NYSE:CANF)41 minutes ago | americanbankingnews.comCan-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver TransplantationSeptember 9, 2026 | globenewswire.comNVDA CEO says it’s a "once-in-a-generation opportunity"NVIDIA CEO Jensen Huang calls a little-known AI niche a once-in-a-generation opportunity, and it has nothing to do with chips or ChatGPT. Huang says AI is moving off computers and into the real world, calling it the dawn of a new industrial revolution. Matt McCall, who flagged NVDA at $6 before it climbed 3,100% in six years, reveals his top pick in this emerging space.September 20 at 1:00 AM | Monument Traders Alliance (Ad)Can-Fite BioPharma (NYSE:CANF) Stock Price Up 2.7% - What's Next?September 9, 2026 | americanbankingnews.comCan-Fite Reports Q2 2026 Results As Liver Cancer Survival Exceeds ExpectationsSeptember 8, 2026 | rttnews.comCan-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer StudySeptember 8, 2026 | globenewswire.comCan-Fite BioPharma Announces $4 Million Warrant ExerciseSeptember 2, 2026 | finance.yahoo.comCan-Fite BioPharma Evaluates Earlier Interim Analysis for Key Liver Cancer StudySeptember 2, 2026 | benzinga.comSee More Headlines CANF Stock Analysis - Frequently Asked Questions How have CANF shares performed this year? Can-Fite BioPharma's stock was trading at $4.00 at the start of the year. Since then, CANF shares have decreased by 44.0% and is now trading at $2.24. How were Can-Fite BioPharma's earnings last quarter? Can-Fite BioPharma Ltd. (NYSE:CANF) posted its quarterly earnings data on Tuesday, November, 30th. The company reported ($38.00) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($18.00) by $20.00. The company had revenue of $0.25 million for the quarter. When did Can-Fite BioPharma's stock split? Shares of Can-Fite BioPharma reverse split on Monday, January 5th 2026.The 1-20 reverse split was announced on Tuesday, December 23rd 2025. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, January 4th 2026. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Can-Fite BioPharma? Shares of CANF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Can-Fite BioPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Can-Fite BioPharma investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Broadcom (AVGO), Novo Nordisk A/S (NVO) and Adobe (ADBE). Company Calendar Last Earnings11/30/2021Today9/19/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 For the last 2 weeks, CANF's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSE:CANF CIK1536196 Webwww.canfite.com Phone972-3-924-1114Fax972-3924-9378Employees5Year FoundedN/APrice Target and Rating Average Price Target for Can-Fite BioPharma$44.00 High Price Target$80.00 Low Price Target$8.00 Potential Upside/Downside+1,864.3%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio2.93 Quick RatioN/A Sales & Book Value Annual Sales$405 thousand Price / Sales3.62 Cash FlowN/A Price / Cash FlowN/A Book Value$1.76 per share Price / Book1.27Miscellaneous Outstanding Shares655,000Free FloatN/AMarket Cap$1.47 million OptionableNot Optionable Beta1.12 Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NYSE:CANF) was last updated on 9/20/2026 by MarketBeat.com Staff. From Our Partners$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | Sponsored“Elon’s nightmare” could fund your retirementMarc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...Chaikin Analytics | SponsoredYou’ve never seen anything like this beforeFor centuries, families like the Rothschilds, Morgans, and Rockefellers have quietly used one overlooked type ...Porter & Company | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredNVDA CEO says it’s a "once-in-a-generation opportunity"NVIDIA CEO Jensen Huang calls a little-known AI niche a once-in-a-generation opportunity, and it has nothing t...Monument Traders Alliance | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Can-Fite BioPharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Can-Fite BioPharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
